Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Abbott India Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 26830, up 3.61% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.71% on the day, quoting at 24444.3. The Sensex is at 78329.41, up 0.73%. Abbott India Ltd has added around 4.07% in last one month.
Meanwhile, Nifty Pharma index of which Abbott India Ltd is a constituent, has added around 6.6% in last one month and is currently quoting at 25745.15, down 0.02% on the day. The volume in the stock stood at 20032 shares today, compared to the daily average of 11080 shares in last one month.
The PE of the stock is 35.39 based on TTM earnings ending March 26.
Abbott India Ltd fell for a fifth straight session today. The stock is quoting at Rs 26020, down 1.03% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.22% on the day, quoting at 23353.3. The Sensex is at 74101.32, down 0.33%.Abbott India Ltd has gained around 2.83% in last one month.Meanwhile, Nifty Pharma index of which Abbott India Ltd is a constituent, has increased around 2.59% in last one month and is currently quoting at 24086.6, up 0.38% on the day. The volume in the stock stood at 2109 shares today, compared to the daily average of 12382 shares in last one month.
The PE of the stock is 36.01 based on TTM earnings ending March 26.
For the full year,net profit rose 9.73% to Rs 1552.02 crore in the year ended March 2026 as against Rs 1414.44 crore during the previous year ended March 2025. Sales rose 8.11% to Rs 6929.05 crore in the year ended March 2026 as against Rs 6409.15 crore during the previous year ended March 2025.
Total operating expenditure for the period under review was Rs 1,228.66 crore, up 4.5% YoY.
Profit before tax in Q4 FY26 stood at Rs 531.23 crore, up by 10.1% from Rs 482.71 crore in Q4 FY25.
For FY26, the company has recorded net profit and revenue from operations of Rs 1552.02 crore (up 9.7% YoY) and Rs 6,929.05 crore (up 8.1% YoY), respectively.
Abbott India is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India.
The scrip fell 1.99% to currently trade at Rs 27224.40 on the BSE.
Profit before tax (PBT) stood at Rs 508.98 crore in Q3 FY26, up 4.38% year on year (YoY).
Total expenses increased 7.20% to Rs 1,284.82 crore in Q3 FY26 as against Rs 1,198.44 crore posted in same quarter last year. The cost of materials consumed stood at Rs 147.31 crore (up 26.88% YoY), employee benefit expense was at Rs 196.07 crore (up 45.58% YoY) and finance cost was at Rs 5.48 crore (up 142.47% YoY) during the period under review.
Shares of Abbott India fell 1.06% to currently trade at Rs 26,609.95 on the BSE.